IR News
by Category
Licensing
Mar. 06, 2023 (PDF/123KB) Licensing
KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
Sep. 30, 2022 (PDF/407KB) Licensing
Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
Aug. 03, 2022 (PDF/162KB) Licensing
Notice of conclusion of sales collaboration for GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos"
Jul. 06, 2022 (PDF/212KB) Licensing
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
May 10, 2022 (PDF/42KB) Licensing
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 05, 2022 (PDF/204KB) Licensing
Sumitomo Pharma and Jazz Pharmaceuticals Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
Mar. 01, 2022 (PDF/171KB) Licensing
JCR and Sumitomo Dainippon Pharma Enter into Marketing Alliance for Agalsidase Beta BS I.V. Infusion [JCR], for Treatment of Fabry Disease in Japan
Nov. 26, 2021 (PDF/201KB) Licensing
Succession of Manufacturing and Marketing Approval and Marketing Rights of REPLAGAL 3.5 mg for Fabry Disease, an α-Galactosidase Enzyme IV Infusion
Oct. 18, 2021 (PDF/247KB) Licensing
Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics
Sep. 30, 2021 (PDF/218KB) Licensing
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds
Sep. 03, 2021 (PDF/215KB) Licensing
Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
Jun. 09, 2021 (PDF/163KB) Licensing
Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"
May 07, 2021 (PDF/135KB) Licensing
Sumitomo Dainippon Pharma Announces Acquisition of Rights for Certain Sinovant Development Compounds in China and Other Asian Countries
Dec. 28, 2020 (PDF/113KB) Licensing
Consolidated Subsidiary Myovant and Pfizer Enter Into Collaboration to Develop and Commercialize Relugolix
Mar. 31, 2020 (PDF/51KB) Licensing
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
Dec. 13, 2019 (PDF/217KB) Licensing
SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
May 30, 2019 (PDF/110KB) Licensing
Sumitomo Dainippon Pharma Signs a Co-Promotion and Sales Collaboration Agreement for Diabetes Treatments Equa and EquMet in Japan
Feb. 26, 2018 (PDF/120KB) Licensing
Sumitomo Dainippon Pharma and JCR Sign a License Agreement on Blood-Brain Barrier Penetration Technology for Creation of a Therapeutic Agent for Central Nervous System Diseases
Feb. 15, 2018 (PDF/232KB) Licensing
Sumitomo Dainippon Pharma Announces Amends the License Agreement for Obeticholic Acid (DSP-1747)
Nov. 21, 2017 (PDF/252KB) Licensing
Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Oct. 30, 2017 (PDF/191KB) Licensing
Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries
Sep. 06, 2017 (PDF/141KB) Licensing
Sumitomo Dainippon Pharma and Maruishi Pharmaceutical concluded a license agreement for an Antiemetic Candidate Compound
Jun. 09, 2017 (PDF/110KB) Licensing
Sumitomo Dainippon Pharma Announces Partnership with Zuellig Pharma on its Carbapenem Antibiotic Meropenem for Five Countries of South-East Asia and Hong Kong
Apr. 07, 2017 (PDF/87KB) Licensing
Sumitomo Dainippon Pharma Announces Partnership with Bukwang on its Atypical Antipsychotic Agent Lurasidone for Korea
Dec. 26, 2016 (PDF/112KB) Licensing
Sumitomo Dainippon Pharma to Conduct Meropenem Business in Five Countries of South-East Asia and Hong Kong
Dec. 22, 2016 (PDF/153KB) Licensing
Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
Jul. 15, 2015 (PDF/122KB) Licensing
Sumitomo Dainippon Pharma Announces Commercialization Partnership with Servier on Its Atypical Antipsychotic Agent Latuda (lurasidone hydrochloride) for Australia
Jul. 09, 2015 (PDF/66KB) Licensing
Eli Lilly Japan and Sumitomo Dainippon Pharma signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos"
May 07, 2015 (PDF/291KB) Licensing
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate their Agreement for the Joint Development and Exclusive Commercialization of Latuda (lurasidone) - an Atypical Antipsychotic Agent, in Europe
Jan. 29, 2015 (PDF/108KB) Licensing
Sumitomo Dainippon Pharma Announces Collaboration on Lurasidone, an Atypical Antipsychotic Agent, for Thailand, Singapore and Hong Kong
Sep. 30, 2014 (PDF/107KB) Licensing
Sumitomo Dainippon Pharma Acquires Patent License from DNAVEC On Clinical-grade iPS Cell Production Technology
Sep. 26, 2014 (PDF/102KB) Licensing
Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North America With Respect to SB623, a Therapy for Stroke
May 26, 2014 (PDF/186KB) Licensing
Dainippon Sumitomo Pharma and Daiichi Sankyo Cooperate on Lurasidone, an Atypical Antipsychotic Agent, in Four South American Countries
Jan. 31, 2014 (PDF/139KB) Licensing
Dainippon Sumitomo Pharma Deepens Cooperation with Edison Pharmaceuticals for Therapeutic Agents for Mitochondria Disease --- Amends the License Agreement and Concludes a Joint Research Agreement and a Stock Purchase Agreement ---
May 08, 2013 (PDF/24KB) Licensing
Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China
Mar. 29, 2013 (PDF/31KB) Licensing
Dainippon Sumitomo Pharma signs a License Agreement with Edison Pharmaceuticals for therapeutic agents for mitochondria disease
Mar. 07, 2013 (PDF/22KB) Licensing
Dainippon Sumitomo Pharma and Nippon Shinyaku conclude a license agreement for SMP-986, a therapeutic agent for urology
Dec. 27, 2012 (PDF/123KB) Licensing
Signing a license agreement and a joint research agreement for new anti-cancer drug candidate compounds targeting the Ras signaling pathway
Jun. 05, 2012 (PDF/40KB) Licensing
Dainippon Sumitomo Pharma and Shionogi to Sign a License Agreement for the Co-marketing of “DSP-8153”, Combination Product of Anti-hypertension Drugs irbesartan and amlodipine besilate
Apr. 27, 2011 (PDF/25KB) Licensing
Dainippon Sumitomo Pharma and Maruho Enter into a License Agreement for a Novel Topical Analgesic Drug
Apr. 07, 2011 (PDF/25KB) Licensing
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
Mar. 30, 2011 (PDF/26KB) Licensing
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
Mar. 30, 2011 (PDF/130KB) Licensing
Takeda and DSP Sign Development, Manufacturing and Commercialization Agreement for a Cephem Antibiotic Ceftaroline in Japan
Mar. 30, 2011 (PDF/199KB) Licensing
DSP and Takeda Sign Development and Commercialization Agreement for an Atypical Antipsychotic Agent Lurasidone in Europe
Oct. 04, 2010 (PDF/125KB) Licensing
Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
Nov. 02, 2007 (PDF/43KB) Licensing
Dainippon Sumitomo Pharma signs license agreement for a sedative hypnotic agent
Jul. 24, 2006 (PDF/57KB) Licensing
Partnership Agreements Concerning Anti-Hypertension & Hepatocellular Cancer Drugs Reached
May 31, 2006 (PDF/139KB) Licensing
Dainippon Sumitomo Pharma and Chelsea Therapeutics International Signed Licensing Agreement for Dops for the treatment of orthostatic hypotension
Apr. 17, 2006 (PDF/14KB) Licensing
Dainippon Sumitomo Pharma and Eisai Signed Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members